Replies to post #15540 on $heff's $tation of $tocks & $olid DD

[rocketeer357]

Also worthy of mention is the August 5 date for an FDA decision on Pennsaid for NRI.TO, NRIFF.PK (.353)

I know it's a grey sheet company, but the volumes have been robust lately. It has dropped from the 52 week high of a week ago, but with such a large float and convertibles paid out at .12, it's easy to see why some would cash in before the decision date.

Covidien bet 10 miilion large on approval. I'm in for a smaller piece of the action, lol.

[Money33]

very nice post

[$heff]

IVOB.OB at .29 now in 3 days from .10 because of the attention surrounding potential clearance of a product in 2010.

On 5/15/09, (6) INVO BioScience (IVOB.OB) ($0.10) provided the following update on obtaining FDA marketing clearance for its fertility technology. INVO technology assists infertile couples in having a baby. In-vitro fertilization (IVF) is an effective treatment option for most infertile couples, and the Company's patented and proven INVOcell technology is a low cost alternative to IVF that is much simpler to perform. INVO uses a device, the INVOcell, which is currently priced at $75-225 to distributors in developing countries and $125-300 in Europe and U.S. While IVOB penetrates the infertility markets in Europe, Canada, and select developing countries, the Company has also completed the first step for medical device companies who manufacture Class 2 devices with the filing of a Premarket Notification 510 (k) submission with the FDA. Technically, the FDA does not "approve" Class 1 and 2 medical devices for sale in the U.S. as the Agency issues "clearance" for them to be sold and marketed. IVOB hopes to receive U.S. marketing clearance by 2010 upon completion of its clinical trial.